Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 9/20 | 1.00 |
| ▸ | CMA1 | P23946 | 4/20 | 1.00 |
| ▸ | MASP2 | O00187 | 1/20 | 0.89 |
| ▸ | ACP3 | P15309 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30355342 | 1.00 | CTSG (1.00) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL30583367 | 1.00 | CTSG (1.00) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL1614372 | 0.95 | CTSG (0.91) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL4455609 | 0.95 | CTSG (0.90) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL10146840 | 0.95 | CTSG (0.90) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL1614715 | 0.94 | CTSG (0.89) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL4462315 | 0.94 | CTSG (0.89) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL31211813 | 0.94 | CTSG (1.00) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL1613660 | 0.94 | CTSG (1.00) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL4456271 | 0.93 | CTSG (0.86) | CTSGCMA1MASP2ACP3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| US-7459461-B2 | Phosphonic acid compounds as inhibitors of serine proteases | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-12-02 | — | — | US | claimed |
| EP-1438316-B1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | ORTHO MCNEIL PHARM INC (US) | 2006-06-21 | — | — | EP | claimed |
| EP-1438316-A1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-07-21 | — | — | EP | claimed |
| US-20040082544-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | claimed |
| US-20030195172-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | GRECO MICHAEL N (US) | 2003-10-16 | — | — | US | claimed |
| WO-2003035654-A1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-05-01 | — | — | WO | claimed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-1620446-A2 | PIPERAZINE CONTAINING PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | Ortho-Mcneil Pharmaceutical Corp. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004094441-A2 | PIPERAZINE CONTAINING PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1438316-A1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040082544-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20030195172-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | GRECO MICHAEL N (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003035654-A1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035654-A1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082544-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | HPN, PRSS1, SERPINB1 | CTSG 251/4885CMA1 137/4885MASP2 31/4885 |
| US-20030195172-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | HPN, PRSS1, SERPINB1 | CTSG 251/4885CMA1 137/4885MASP2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.